Abstract：
There is limited knowledge on how local cytokine secretion patterns after nasal allergen challenge correlate with clinical symptoms especially with regard to the \"late allergic response,\" which occurs in approximately 40% to 50% of patients with allergy.
We sought to characterize the immunologic and clinical nasal responses to birch pollen allergen challenge with a special focus on the late allergic response.
In this randomized, double-blind, placebo-controlled trial, birch pollen-allergic participants were challenged with birch pollen extract (n = 20) or placebo (n = 10) on 3 consecutive days. On days 1 and 3, nasal secretions were collected at selected time points over a 24-hour time course for the measurement of 33 inflammatory mediators. Clinical responses were determined through subjective symptom scores and objective nasal airflow measurements.
Provoked participants had significantly greater clinical responses and showed significant increases in tryptase and the soluble IL-33 receptor serum stimulation 2 (sST2) in nasal secretions within minutes compared with the placebo group. Eight of 20 provoked participants displayed high IL-13 levels 2 to 8 hours after allergen provocation. This group also showed significant changes in clinical parameters, with a secondary drop in nasal airflow measured by peak nasal inspiratory flow and increased symptoms of nasal obstruction, which significantly differed from IL-13 nonresponders after 6 hours.
IL-13 response status correlates with clinical responses and type 2 cytokine responses in the late phase after allergen provocation.
We sought to characterize the immunologic and clinical nasal responses to birch pollen allergen challenge with a special focus on the late allergic response.
In this randomized, double-blind, placebo-controlled trial, birch pollen-allergic participants were challenged with birch pollen extract (n = 20) or placebo (n = 10) on 3 consecutive days. On days 1 and 3, nasal secretions were collected at selected time points over a 24-hour time course for the measurement of 33 inflammatory mediators. Clinical responses were determined through subjective symptom scores and objective nasal airflow measurements.
Provoked participants had significantly greater clinical responses and showed significant increases in tryptase and the soluble IL-33 receptor serum stimulation 2 (sST2) in nasal secretions within minutes compared with the placebo group. Eight of 20 provoked participants displayed high IL-13 levels 2 to 8 hours after allergen provocation. This group also showed significant changes in clinical parameters, with a secondary drop in nasal airflow measured by peak nasal inspiratory flow and increased symptoms of nasal obstruction, which significantly differed from IL-13 nonresponders after 6 hours.
IL-13 response status correlates with clinical responses and type 2 cytokine responses in the late phase after allergen provocation.
摘要：
背景：关于鼻过敏原激发后局部细胞因子分泌模式如何与临床症状相关的知识有限，尤其是在大约40-50％的过敏患者中发生的“晚期过敏反应”（LAR）方面。
目的：在这项研究中，我们旨在表征对桦树花粉过敏原攻击的免疫和临床鼻反应，特别关注LAR。
方法：在这项随机双盲安慰剂对照试验中，连续3天接受花粉提取物(n=20)或安慰剂(n=10)攻击桦树花粉过敏参与者.在第1天和第3天,在24小时时间过程中在选定的时间点收集鼻分泌物,用于测量33种炎性介质。通过主观症状评分和客观鼻气流测量确定临床反应。
结果：与安慰剂相比，被激发的参与者的临床反应明显更大，并且在几分钟内显示出类胰蛋白酶和sST2的显着增加。20名被激发的参与者中有8名在过敏原激发后2-8小时显示出高IL-13水平。该组还显示出临床参数的显着变化，通过峰值鼻吸气流量测量的鼻气流二次下降，鼻塞症状增加，这与6小时的IL-13无反应者显着不同。
结论：IL-13反应状态与过敏原激发后晚期的细胞因子和临床反应相关。
目的：在这项研究中，我们旨在表征对桦树花粉过敏原攻击的免疫和临床鼻反应，特别关注LAR。
方法：在这项随机双盲安慰剂对照试验中，连续3天接受花粉提取物(n=20)或安慰剂(n=10)攻击桦树花粉过敏参与者.在第1天和第3天,在24小时时间过程中在选定的时间点收集鼻分泌物,用于测量33种炎性介质。通过主观症状评分和客观鼻气流测量确定临床反应。
结果：与安慰剂相比，被激发的参与者的临床反应明显更大，并且在几分钟内显示出类胰蛋白酶和sST2的显着增加。20名被激发的参与者中有8名在过敏原激发后2-8小时显示出高IL-13水平。该组还显示出临床参数的显着变化，通过峰值鼻吸气流量测量的鼻气流二次下降，鼻塞症状增加，这与6小时的IL-13无反应者显着不同。
结论：IL-13反应状态与过敏原激发后晚期的细胞因子和临床反应相关。
